Home » Stocks » Eidos Therapeutics

Eidos Therapeutics, Inc. (EIDX)

Stock Price: $46.23 USD -0.48 (-1.02%)
Updated Jul 14, 2020 12:26 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.78B
Revenue (ttm) 26.69M
Net Income (ttm) -48.93M
Shares Out 38.54M
EPS (ttm) -1.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 14, 2020
Last Price $46.23
Previous Close $46.70
Change ($) -0.48
Change (%) -1.02%
Day's Open 46.72
Day's Range 44.99 - 47.51
Day's Volume 41,989
52-Week Range 28.00 - 66.56

More Stats

Market Cap 1.78B
Enterprise Value 1.61B
Earnings Date (est) Aug 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 38.54M
Float 10.96M
EPS (basic) -1.31
EPS (diluted) -1.32
FCF / Share -1.07
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.96M
Short Ratio 17.22
Short % of Float 17.86%
Beta -0.28
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 66.74
PB Ratio 10.76
Revenue 26.69M
Operating Income -50.75M
Net Income -48.93M
Free Cash Flow -40.70M
Net Cash 175.19M
Net Cash / Share 4.55
Gross Margin 90.63%
Operating Margin -190.15%
Profit Margin -183.30%
FCF Margin -152.47%
ROA -16.84%
ROE -30.66%
ROIC -345.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 5
Overweight 0
Hold 2
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

(20.32% upside)
Current: 46.23
Target: 55.62
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit24.19---
Operating Income-40.45-37.78-12.02-2.39
Net Income-37.84-40.73-11.94-2.54
Shares Outstanding36.6221.373.602.60
Earnings Per Share-1.03-1.86-3.32-0.98
Operating Cash Flow-31.65-33.30-9.72-2.06
Capital Expenditures-0.23-0.15-0.05-
Free Cash Flow-31.88-33.45-9.77-2.06
Cash & Equivalents1911575.500.00
Total Debt21.26---
Net Cash / Debt1701575.500.00
Book Value171155-13.20-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Eidos Therapeutics, Inc.
Country United States
Employees 47
CEO Neil Kumar

Stock Information

Ticker Symbol EIDX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: EIDX
IPO Date June 20, 2018


Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma LLC.